Teva and Lilly Legal Dispute, Dementia Study Updates

Good morning, everyone. As we embark on another busy day, the weather looks promising despite forecasts of rising temperatures. The skies are clear, and the sounds of nature provide a pleasant backdrop on the Pharmalot campus. To celebrate the beautiful day, we indulge in a refreshing hot drink and a delicious slice of pecan pie. However, the focus now shifts to our pressing agenda, which includes several intriguing updates in the pharmaceutical sector.

A significant development involves a U.S. appeals court that has revived a lawsuit filed by Teva Pharmaceuticals against Eli Lilly, which accuses Lilly of breaching an agreement related to Teva’s generic version of the osteoporosis medication Forteo. According to reports, the appeals court overturned a previous ruling by a lower court, which had determined that the agreement had expired before Lilly allegedly violated it.

The legal battle dates back to 2016 when Lilly initiated a lawsuit against Teva for patent infringement. The two companies eventually reached a settlement in 2018, allowing Teva to begin marketing its generic version of Forteo in 2019, just as Lilly's patents were set to expire. However, in 2020, the U.S. Food and Drug Administration granted Lilly an additional three years of exclusivity for Forteo, complicating matters further. Teva proceeded to launch its generic drug in 2023 and subsequently filed a lawsuit in 2024. In its complaint, Teva argues that Lilly’s extended exclusivity period unlawfully delayed their product launch.

In another noteworthy announcement, a groundbreaking study has been initiated with an investment of $100 million to investigate whether lifestyle modifications, combined with GLP-1 agonists or similar treatments, could lower the risk of dementia. The PROTECT-Cog study, unveiled during the 2026 Alzheimer’s Association International Congress in London, will last three years and is based on previous research suggesting that lifestyle changes can enhance memory, cognitive function, and overall thinking abilities. This research will involve older individuals at higher risk of cognitive decline and will compare the effectiveness of two distinct lifestyle-change programs—one more intensive and the other moderately structured—both with and without accompanying drug treatments. Stay tuned for further updates on these significant developments.